Rice Hall James & Associates’s UroGen Pharma URGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.94M | Buy |
287,874
+32,083
| +13% | +$440K | 0.21% | 100 |
|
|
2025
Q1 | $2.83M | Sell |
255,791
-8,240
| -3% | -$91.1K | 0.17% | 130 |
|
|
2024
Q4 | $2.81M | Sell |
264,031
-7,866
| -3% | -$83.8K | 0.15% | 145 |
|
|
2024
Q3 | $3.45M | Buy |
271,897
+199,110
| +274% | +$2.53M | 0.19% | 123 |
|
|
2024
Q2 | $1.22M | Buy |
72,787
+2,381
| +3% | +$40K | 0.07% | 197 |
|
|
2024
Q1 | $1.06M | Buy |
70,406
+514
| +0.7% | +$7.71K | 0.06% | 208 |
|
|
2023
Q4 | $1.05M | Sell |
69,892
-5,288
| -7% | -$79.3K | 0.06% | 214 |
|
|
2023
Q3 | $1.05M | Sell |
75,180
-907
| -1% | -$12.7K | 0.07% | 202 |
|
|
2023
Q2 | $788K | Buy |
76,087
+2,882
| +4% | +$29.8K | 0.04% | 230 |
|
|
2023
Q1 | $676K | Buy |
73,205
+274
| +0.4% | +$2.53K | 0.04% | 240 |
|
|
2022
Q4 | $647K | Sell |
72,931
-1,500
| -2% | -$13.3K | 0.04% | 242 |
|
|
2022
Q3 | $619K | Sell |
74,431
-36,026
| -33% | -$300K | 0.04% | 242 |
|
|
2022
Q2 | $905K | Buy |
110,457
+2,467
| +2% | +$20.2K | 0.04% | 231 |
|
|
2022
Q1 | $941K | Buy |
107,990
+6,631
| +7% | +$57.8K | 0.04% | 242 |
|
|
2021
Q4 | $964K | Sell |
101,359
-47,901
| -32% | -$456K | 0.03% | 246 |
|
|
2021
Q3 | $2.51M | Sell |
149,260
-92,377
| -38% | -$1.55M | 0.09% | 170 |
|
|
2021
Q2 | $3.69M | Sell |
241,637
-45,168
| -16% | -$690K | 0.13% | 119 |
|
|
2021
Q1 | $5.59M | Buy |
286,805
+184,752
| +181% | +$3.6M | 0.18% | 101 |
|
|
2020
Q4 | $1.84M | Buy |
+102,053
| New | +$1.84M | 0.06% | 208 |
|